22 results about "Ischemic brain" patented technology

Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The invention discloses low-temperature injectable hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Hydrogel is prepared from high-molecular-weight hyaluronic acid grafted with vitamin E and poly (N-isopropylacrylamide), the hydrogel is in an injectable liquid state at 4 DEG C, and a drug capsaicin (CPZ) wrapped by micelle is loaded and injected into the brain from the brain in a stereotactic mode. The pharmaceutical composition can temporarily maintain local low temperature of brain tissue and release capsaicin, reduce local metabolic activity of ischemic brain tissue, temporarily inhibit biogenesis, reduce NADH, FADH2 and other reducing equivalents and ADP accumulation, reduce the possibility of electron leakage in an electron transport chain, and improve the bioavailability of ischemic brain tissue. Vitamin E is added to reduce superoxide anions (O2 <.->) generated by reduction reaction of oxygen and leaked electrons in the reperfusion process, and vitamin E can promote ROS removal, synergistically alleviate oxidative stress and subsequent inflammation, and comprehensively improve cerebral ischemia reperfusion injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The present invention relates to a composition containing gintonin as an active ingredient for the prevention and treatment of ischemic cerebrovascular disorders, including cerebral infarction. The gintonin of the present invention can reduce the volume of cerebral infarction and increase survival rates after cerebral infarction, making it useful for the prevention and treatment of cerebral infarction. Furthermore, pretreatment of human brain microvascular endothelial cells (HBMECs) with gintonin has been shown to have neuroprotective and injury-preventing effects, while posttreatment with gintonin has been shown to have neuroprotective and therapeutic effects. Mechanism verification revealed that gintonin is effective in restoring reduced nitric oxide (NO) levels, which are known to be involved in the onset and pathophysiology of cerebral infarction. Therefore, the use of the present invention may improve the prevention and treatment of ischemic cerebrovascular disorders, including cerebral infarction, and reduce medical costs.

A method for treating brain injury in a subject comprises administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant. The protein variant is delivered systemically and can reduce tissue damage after ischemic brain tissue reperfusion. The methods specifically involve the use of G415R mutants of PKM2 protein variants. The treatment is suitable for brain injury caused by hemorrhagic stroke and ischemic stroke. The PKM2 protein variants are ideally administered intravenously within one hour of reperfusion to maximize their therapeutic efficacy.

The invention relates to systems and methods for predicting ischemic brain tissue fate from multi-phase CT-angiography. More specifically, systems and methods are provided that enable meaningful prediction of core, penumbra and perfusion from mCTA images using software that has been trained via machine learning to interpret mCTA images.

The invention relates to a polypeptide of SEQ ID NO: 1 for use in the treatment of acute ischaemic stroke (AIS) or in the prevention of the complications of AIS in an adult mammalian subject. The polypeptide can be used in patients in whom AIS is followed by reperfusion of ischemic brain tissue, or in patients in whom AIS is not followed by reperfusion of ischemic brain tissue (patients with permanent cerebral ischemia).

The invention belongs to the technical field of biological medicine, and particularly relates to application of phthalide isoquinoline alkaloid in corydalis amabilis to preparation of a medicine for resisting cerebral ischemia. According to the application disclosed by the invention, corydalis amabilis with definite anti-cerebral ischemia activity is taken as a research object, and the anti-cerebral ischemia activity target P21 protein activating enzyme 2 of the corydalis amabilis is obtained and identified from ischemic brain tissues of middle cerebral artery occlusion (MCAO) rats by using a molecular target'hooking 'technology based on thermal proteomics. Then, the inventor detects the binding force of a monomeric compound and a target protein in corydalis amabilis by using a surface plasmon resonance technology, and finally screens out a key substance phthalide isoquinoline alkaloid, which exerts the anti-cerebral ischemia activity, in corydalis amabilis.

The present application relates to the use of compound 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidine)] benzenesulfonyl]-3,5-dimethylpiperazine, particularly in the preparation of drugs for the prevention and treatment of diseases caused by cerebral ischemia, particularly ischemic cerebral neuron damages and necrosis.

The invention discloses application of a reagent for detecting abundance of intestinal flora markers in preparation of a cerebral apoplexy in-vitro diagnosis product. The method comprises the following steps: performing 16S v4 region amplicon sequencing on bacterial components in faeces of healthy people and cerebral arterial thrombosis people to obtain the abundance of bacteria, finding out flora of 18 specific genus and species as microbial markers through screening operation, and constructing a cerebral arterial thrombosis risk prediction model. Verification queue data proves that the cerebral arterial thrombosis risk prediction model is high in prediction sensitivity and good in specificity, cerebral arterial thrombosis patients and healthy individuals can be effectively distinguished in multiple samples, and the accuracy is 93% or above, so that the flora can be used as a cerebral arterial thrombosis detection marker, and the cerebral arterial thrombosis risk prediction model can be used for detecting cerebral arterial thrombosis. A reagent for detecting the abundance of the intestinal flora marker can be used for preparing a cerebral arterial thrombosis in-vitro diagnosis kit, so that a foundation is laid for early diagnosis, prevention and treatment as well as research of cerebral arterial thrombosis.

The present application relates to a gene for regulating cholesterol metabolism and a micropeptide MP19 encoded thereby, and a use thereof, and also relates to a use of the micropeptide in the preparation of a drug or pharmaceutical composition for detecting, preventing, alleviating or treating diseases associated with abnormal cholesterol metabolism, said diseases comprising atherosclerosis, age-related macular degeneration, hyperlipidemia, non-alcoholic hepatitis, hepatocellular carcinoma, coronary heart disease, ischemic stroke, and obesity. By means of endogenous overexpression or exogenous synthesis of the micropeptide, diseases associated with abnormal cholesterol metabolism can be effectively prevented, alleviated, or treated.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

The invention relates to systems and methods for predicting ischemic brain tissue fate from multi-phase CT-angiography. More specifically, systems and methods are provided that enable meaningful prediction of core, penumbra and perfusion from mCTA images using software that has been trained via machine learning to interpret mCTA images.

The invention discloses a marker combination for predicting the mortality risk of a patient suffering from acute ischemic cerebral infarction after etiotyping and thrombus extraction and application of the marker combination, and relates to the technical field of medical treatment. The key points of the technical scheme are as follows: the application of the marker in pathogenesis typing of the acute ischemic cerebral infarction patient and / or prediction of the death risk of the acute ischemic cerebral infarction patient after thrombus extraction is provided; the marker is a protein combination ML15 which comprises AGER, TNFRSF13B, CRIM1, ESM1, LAMP3, PRELP, LY6D, IL17D, CNTNAP2, EPO, CLSTN2, NTF3, GAL, OMD and MATN2; the effects of realizing high-precision prediction of the death risk of the patient within one year after thrombectomy, providing a key window for early intervention and analyzing pathogenesis are achieved.

This invention relates to the application of compound ID-8 in the preparation of drugs for treating ischemic cerebrovascular diseases. This invention demonstrates the protective effect of ID-8 on ischemic brain. Research data shows that ID-8 can significantly reduce brain tissue damage and cell death caused by ischemic stroke, shrink infarct foci, and improve neurological function. Compound ID-8 can be used to prepare drugs for treating ischemic cerebrovascular diseases, can be combined with various excipients, can be combined with various existing drugs for treating ischemic cerebrovascular diseases, and is applicable to various dosage forms and routes of administration. This results in novel, safe, and effective drugs and treatments for ischemic cerebrovascular diseases that can reduce brain ischemia-related damage, and has significant clinical and social value.

The present invention relates to compounds of formula (I) and to the addition salts thereof with a pharmaceutically acceptable acid, for the treatment of non-traumatic acquired brain injury, wherein M represents NR 1 R 2 group, OR 1 group or SR 1 group, A represents NR 4 R 5 group, OR 10 group or a hydrogen atom, R 3 is (C1-C6)alkyl, (C1-C6)cycloalkyl, aryl, -CH2-aryl, CH2-(C1-C6)cycloalkyl or -CH2-heteroaryl. The present invention further relates to compounds of formula (I) wherein R 5 is (C1-C8)alkyl or (C1-C6)cycloalkyl, said alkyl and cycloalkyl being substituted by one, two or three -OCOR a groups.

The application relates to application of Danshensu borneol ester related substances in treatment of ischemic brain and cardiovascular diseases. In particular, the application relates to use of Danshensu borneol ester isomers and derivatives thereof in preparation of medicines for preventing and treating ischemic cerebrovascular diseases and cardiovascular diseases, and belongs to the technical field of medicines.

The invention discloses a health monitoring method based on combination of body fluid SERS spectrum and B ultrasonic image, comprising the following steps: S1, collecting data of a monitored person, the data comprising physiological indexes, urine and carotid artery ultrasonic image, processing the urine to obtain SERS signals, processing the SERS signals to obtain first feature data, and processing the first feature data to obtain second feature data; processing the carotid artery ultrasonic image through an Alexnet model framework to obtain second feature data; s2, taking the first feature data and the second feature data as independent data, performing model prediction to obtain a first probability based on the first feature data and a second probability based on the second feature data, then taking the obtained first probability and second probability as new independent parameters, combining the new independent parameters with the physiological indexes, and performing model prediction again to obtain a model prediction result; when the output result is 1, the risk of suffering from the cerebral arterial thrombosis is indicated. And the SERS spectrum of the body fluid and the B ultrasonic image are combined for judgment, so that the accuracy of a monitoring result can be effectively improved, and a monitor can conveniently and further see a doctor for treatment.

The invention relates to a traditional Chinese medicine component compound. The traditional Chinese medicine component compound comprises baicalin, salidroside and catalpol. The traditional Chinese medicine component compound disclosed by the invention is a traditional Chinese medicine compound, pays attention to enhancement of an autoimmune system, and is free of toxic and side effects and reasonable in formula; the traditional Chinese medicine composition effectively aims at main pathogenesis of ischemic encephaledema and cerebral ischemia, such as reduction of cerebral moisture content, reduction of cerebral ischemia area, alleviation of neurological dysfunction, reduction of neuronal apoptosis and the like, and has a remarkable curative effect; the raw materials are wide in source and easy to obtain, can be extracted and biosynthesized by adopting crude drugs, can also be directly used as chemical synthesis products, and are convenient for preparation and large-scale production.

The application discloses application of sh-SLK in preparation of a preparation for relieving cerebral ischemia-reperfusion injury, and relates to the technical field of gene targeting drugs. An effective active component of the preparation comprises short hairpin RNA sh-SLK capable of targeting and specifically silencing STE20-like kinase gene expression. The preparation is loaded in a recombinant virus carrier, and is formulated into a lateral cerebral ventricle injection dosage form; the preparation is delivered to brain tissues through a brain stereotactic technique, so that high-efficiency expression of sh-SLK is established in ischemic brain tissues, and then the activity of SLK is specifically inhibited.